With advances in next generation sequencing, the application of this paradigm in breast cancer has progressed from identification of hormone receptor and HER-2 expression to genomic profiling of tumors to assess a range of gene expression levels and identify mutations in specific genes that may drive tumor progression and offer targets for therapeutic intervention [4–6]. The gene discussed is ERBB2; the disease is breast cancer.